All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-04-19T07:51:23.000Z

FDA grants Orphan Drug Designation Status for tasquinimod to treat MM

Apr 19, 2017
Share:

Bookmark this article

On 12th April 2017, tasquinimod from Active Biotech AB (Nasdaq Stockholm: ACTI) was granted Orphan Drug Designation status by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM)1.  

Tasquinimod is a small molecule (second-generation quinoline-3-carboxamide variant) immunomodulatory drug that targets the tumor microenvironment by controlling metastatic and angiogenic function of myeloid derived suppressor cells (MDSCs). Specifically, it binds to the pro-inflammatory protein S100A9 (also known as migration inhibitory factor-related protein 14, MRP14), blocking its interaction with receptors TLR4, RAGE, and CD1472

Previous development of tasquinimod focused on prostate cancer, with promising outcomes in phase 2 and 3 trials. Recently, pre-clinical studies using MM models have shown promising antitumor effects, including a significant reduction in angiogenesis in the bone marrow. 

 

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox